Accéder au contenu
Merck
Toutes les photos(3)

Key Documents

View All Documentation

911860

Sigma-Aldrich

NanoFabTx™ microfluidic - micro

device kit for synthesis of 1-5 μm particles

Synonyme(s) :

Microfluidic kit, Microparticle, NanoFabTx™ device kit, Nanoformulation

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(3)

About This Item

Code UNSPSC :
12162002
Code UNSPSC :
41121811
Nomenclature NACRES :
NA.23

Description

Microfludic device kit for synthesizing 1-5 μm microparticles

Kit components :

  • Microfluidic chip x 1
  • Tubings and accessories

Niveau de qualité

100

Application(s)

advanced drug delivery

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

NanoFabTx™ Microfluidic - micro device kit includes a comprehensive protocol, pre-assembled microfluidic chip manifold, tubing, and accessories—a microfluidic platform to synthesize drug-encapsulating microparticles 1-5 μm in size. It is compatible with either a standard syringe pump (not included) or the Dolomite microfluidics system (not included). The device kit does not include reagents. NanoFabTx™- micro reagent kits, like NanoFabTx™ PLGA-micro (Cat.No. 912220) provide the reagents for the synthesis of 1-5 μm PLGA microparticles.

Application

NanoFabTx™ Microfluidic - micro device kit is designed to work with the NanoFabTx™- micro reagent kits for the synthesis of 1-5 μm particles (Cat.No. 912220) and can be used to create drug-encapsulated polymeric microspheres with narrow size-dispersity and consistent drug loading. Polymeric microparticles also can encapsulate larger biologics like proteins, mRNA, and DNA, in addition to drugs and small molecules, and may serve as vehicles for targeted delivery and controlled release. Microfluidic-based synthesis is a powerful tool in drug development for fabricating size-controlled drug-delivery particles, enabling scalable synthesis of particles and rapid formulation screening. In contrast to nanoprecipitation or solvent-displacement methods, microfluidic technologies have several advantages including enhanced reproducibility, less consumption of expensive reagents, and superior scalability.

Caractéristiques et avantages

  • Step-by-step microfluidic-based protocols developed and tested by our formulation scientists
  • Optimized to make monodisperse microparticles of any size between 1 and 5 μm
  • Facilitates simple optimization of drug encapsulation and loading efficiency in microparticles

Informations légales

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

911593

NanoFabTx™ microfluidic - nano, device kit for synthesis of 100-200 nm nanoparticles and liposomes

911860

NanoFabTx™ microfluidic - micro, device kit for synthesis of 1-5 μm particles

911879

NanoFabTx™ microfluidic - micro, device kit for synthesis of 10-30 μm particles

909637

NanoFabTx™ PLGA-nano, for synthesis of 100 and 200 nm particles

912212

NanoFabTx™ PLGA-micro, for synthesis of 10-30 um particles

912220

NanoFabTx™ PLGA-micro, for synthesis of 1-5 μm particles

920436

NanoFabTx™ PEG-PLA drug formulation screening kit, for synthesis of PEGylated nanoparticles

915408

NanoFabTx™ PEGylated nanoparticle formulation screening kit

917796

NanoFabTx™ PEG-PLGA drug formulation screening kit, for synthesis of PEGylated nanoparticles

918881

NanoFabTx™ PEG-PCL drug formulation screening kit, for synthesis of PEGylated nanoparticles

918075

NanoFabTx™ PLA-nano, for synthesis of 100 and 200 nm particles

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Andrew Gdowski et al.
Journal of nanobiotechnology, 16(1), 12-12 (2018-02-13)
The process of optimization and fabrication of nanoparticle synthesis for preclinical studies can be challenging and time consuming. Traditional small scale laboratory synthesis techniques suffer from batch to batch variability. Additionally, the parameters used in the original formulation must be
Xuanyu Li et al.
Advanced drug delivery reviews, 128, 101-114 (2017-12-27)
Microfluidic chips allow the rapid production of a library of nanoparticles (NPs) with distinct properties by changing the precursors and the flow rates, significantly decreasing the time for screening optimal formulation as carriers for drug delivery compared to conventional methods.
Samar Damiati et al.
Genes, 9(2) (2018-02-22)
Microfluidic devices present unique advantages for the development of efficient drug carrier particles, cell-free protein synthesis systems, and rapid techniques for direct drug screening. Compared to bulk methods, by efficiently controlling the geometries of the fabricated chip and the flow

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique